Alexandra Nelson

Alexandra Nelson


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in Neuron
Verified
Journal Article
Closed access
MMMatthew M. McGregor
Matthew M. McGregor
ANAlexandra Nelson
Alexandra Nelson

1 June 2018 in Cell Reports
Verified
Journal Article
Open access
MRMichael B. Ryan
Michael B. Ryan
CBChloe Bair-Marshall
Chloe Bair-Marshall
ANAlexandra Nelson
Alexandra Nelson
Action selection relies on the coordinated activity of striatal direct and indirect pathway medium spiny neurons (dMSNs and iMSNs, respectively). Loss of dopamine in Parkinson's disease is thought to disrupt this balance. While dopamine replacement with levodopa may restore normal function, the development of involuntary movements (levodopa-induced dyskinesia [LID]) limits therapy. How chronic dopamine loss and replacement with levodopa modulate the firing of identified MSNs in behaving animals is unknown. Using optogenetically labeled striatal single-unit recordings, we assess circuit dysfunction in parkinsonism and LID. Counter to current models, we found that following dopamine depletion, iMSN firing was elevated only during periods of immobility, while dMSN firing was dramatically and persistently reduced. Most notably, we identified a subpopulation of dMSNs with abnormally high levodopa-evoked firing rates, which correlated specifically with dyskinesia. These findings provide key insights into the circuit mechanisms underlying parkinsonism and LID, with implications for developing targeted therapies.

1 February 2018 in Neuron
Verified
Journal Article
Closed access
AGAllison E. Girasole
Allison E. Girasole
MLMatthew Y. Lum
Matthew Y. Lum
DNDiane Nathaniel
Diane Nathaniel
CBChloe J. Bair-Marshall
Chloe J. Bair-Marshall
CGCasey J. Guenthner
Casey J. Guenthner
ANAlexandra Nelson
Alexandra Nelson

1 November 2019 in Cell Reports
Verified
Journal Article
Open access
MMMatthew M. McGregor
Matthew M. McGregor
GMGabriel L. McKinsey
Gabriel L. McKinsey
AGAllison E. Girasole
Allison E. Girasole
CBChloe J. Bair-Marshall
Chloe J. Bair-Marshall
JRJohn L.R. Rubenstein
John L.R. Rubenstein
ANAlexandra Nelson
Alexandra Nelson
One long-standing model of striatal function divides the striatum into compartments called striosome and matrix. While some anatomical evidence suggests that these populations represent distinct striatal pathways with differing inputs and outputs, functional investigation has been limited by the methods for identifying and manipulating these populations. Here, we utilize hs599CreER mice as a new tool for targeting striosome projection neurons and testing their functional connectivity. Extending anatomical work, we demonstrate that striosome neurons receive greater synaptic input from prelimbic cortex, whereas matrix neurons receive greater input from primary motor cortex. We also identify functional differences in how striosome and matrix neurons process excitatory input, providing the first electrophysiological method for delineating striatal output neuron subtypes. Lastly, we provide the first functional demonstration that striosome neurons are the predominant striatal output to substantia nigra pars compacta dopamine neurons. These results identify striosome and matrix as functionally distinct striatal pathways.

4 July 2022 in eLife
Verified
Journal Article
Open access
JSJonathan S Schor
Jonathan S Schor
IMIsabelle Gonzalez Montalvo
Isabelle Gonzalez Montalvo
PSPerry We Spratt
Perry We Spratt
RBRea J Brakaj
Rea J Brakaj
JSJasmine A Stansil
Jasmine A Stansil
ANAlexandra Nelson
Alexandra Nelson
Subthalamic nucleus deep brain stimulation (STN DBS) relieves many motor symptoms of Parkinson’s disease (PD), but its underlying therapeutic mechanisms remain unclear. Since its advent, three major theories have been proposed: (1) DBS inhibits the STN and basal ganglia output; (2) DBS antidromically activates motor cortex; and (3) DBS disrupts firing dynamics within the STN. Previously, stimulation-related electrical artifacts limited mechanistic investigations using electrophysiology. We used electrical artifact-free GCaMP fiber photometry to investigate activity in basal ganglia nuclei during STN DBS in parkinsonian mice. To test whether the observed changes in activity were sufficient to relieve motor symptoms, we then combined electrophysiological recording with targeted optical DBS protocols. Our findings suggest that STN DBS exerts its therapeutic effect through the disruption of movement-related STN activity, rather than inhibition or antidromic activation. These results provide insight into optimizing PD treatments and establish an approach for investigating DBS in other neuropsychiatric conditions.

2 January 2024 in The Cerebellum
Verified
Journal Article
Open access
PDF file
LSLouisa P. Selvadurai
Louisa P. Selvadurai
SPSusan L. Perlman
Susan L. Perlman
TATetsuo Ashizawa
Tetsuo Ashizawa
GWGeorge R. Wilmot
George R. Wilmot
COChiadi U. Onyike
Chiadi U. Onyike
JSJeremy D. Schmahmann
Jeremy D. Schmahmann
The Cerebellar Cognitive Affective/Schmahmann Syndrome (CCAS) manifests as impaired executive control, linguistic processing, visual spatial function, and affect regulation. The CCAS has been described in the spinocerebellar ataxias (SCAs), but its prevalence is unknown. We analyzed results of the CCAS/Schmahmann Scale (CCAS-S), developed to detect and quantify CCAS, in two natural history studies of 309 individuals Symptomatic for SCA1, SCA2, SCA3, SCA6, SCA7, or SCA8, 26 individuals Pre-symptomatic for SCA1 or SCA3, and 37 Controls. We compared total raw scores, domain scores, and total fail scores between Symptomatic, Pre-symptomatic, and Control cohorts, and between SCA types. We calculated scale sensitivity and selectivity based on CCAS category designation among Symptomatic individuals and Controls, and correlated CCAS-S performance against age and education, and in Symptomatic patients, against genetic repeat length, onset age, disease duration, motor ataxia, depression, and fatigue. Definite CCAS was identified in 46% of the Symptomatic group. False positive rate among Controls was 5.4%. Symptomatic individuals had poorer global CCAS-S performance than Controls, accounting for age and education. The domains of semantic fluency, phonemic fluency, and category switching that tap executive function and linguistic processing consistently separated Symptomatic individuals from Controls. CCAS-S scores correlated most closely with motor ataxia. Controls were similar to Pre-symptomatic individuals whose nearness to symptom onset was unknown. The use of the CCAS-S identifies a high CCAS prevalence in a large cohort of SCA patients, underscoring the utility of the scale and the notion that the CCAS is the third cornerstone of clinical ataxiology.